BioCentury | Feb 16, 2015
Company News

ActoGeniX, Intrexon deal

...an ActoBiotic genetically modified to express and secrete human trefoil factor 3 (TFF3) and AG014...
...Ib testing to treat and prevent oral mucositis (OM) in head and neck cancer patients. AG014...
BioCentury | Feb 14, 2015
Company News

Intrexon acquires mucosal therapeutics play ActoGeniX

...factor 3 ( TFF3 ), is in Phase II testing for oral mucositis and stomatitis. AG014...
BioCentury | Nov 10, 2014
Clinical News

AG014: Phase I data

...trial in healthy volunteers showed that oral AG014 was well tolerated. Pharmacokinetic data showed that AG014...
...of AG014 in 2015, with data slated for 1H16. ActoGeniX N.V. , Zwijnaarde, Belgium Product: AG014...
Items per page:
1 - 3 of 3